Affinity Asset Advisors’s Mersana Therapeutics MRSN Stock Holding History

Affinity Asset Advisors’s Portfolio MRSN Stock Details MRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-100,000	Closed	-$2.89M	–	113
2025 Q4	$2.89M	Buy	+100,000	New	+$1.9M	0.16%	75
2024 Q3	–	Sell	-30,680	Closed	-$1.54M	–	97
2024 Q2	$1.54M	Sell	30,680 -9,320	-23%	-$674K	0.18%	71
2024 Q1	$4.48M	Hold	40,000	–	–	0.55%	53
2023 Q4	$2.32M	Sell	40,000 -74,000	-65%	-$2.98M	0.42%	54
2023 Q3	$3.62M	Buy	+114,000	New	+$5.42M	1.02%	34
2021 Q3	–	Sell	-3,400	Closed	-$1.15M	–	87
2021 Q2	$1.15M	Hold	3,400	–	–	0.41%	50
2021 Q1	$1.38M	Buy	3,400 +1,400	+70%	+$679K	0.47%	43
2020 Q4	$1.33M	Buy	+2,000	New	+$1.11M	0.71%	36

Other funds holding MRSN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Affinity Asset Advisors's MRSN Position: Q1 2026 in Review

Affinity Asset Advisors sold out of Mersana Therapeutics (MRSN) in Q1 2026, closing a stake of 100,000 shares — an estimated $2.89M sold.

Affinity Asset Advisors first reported a position in MRSN in Q4 2020 and held it in 8 quarters. The position peaked at $4.48M in Q1 2024. 1 fund tracked by Wall St. Rank holds MRSN as of Q1 2026.

Affinity Asset Advisors reported no remaining Mersana Therapeutics position as of Q1 2026 after selling out during the quarter.
Affinity Asset Advisors sold 100,000 Mersana Therapeutics shares in Q1 2026, an estimated $2.89M.
Affinity Asset Advisors first reported a position in Mersana Therapeutics in Q4 2020 and held it in 8 quarters.
Affinity Asset Advisors's Mersana Therapeutics position peaked at $4.48M in Q1 2024.
1 fund tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2026.

Based on Affinity Asset Advisors's 13F filing for Q1 2026, filed 14 May 2026.